Results 41 to 50 of about 6,848 (153)

Expert opinion on the use of cladribine tablets in clinical practice

Therapeutic Advances in Neurological Disorders, 2020
Background: Gaps in current product labels and a lack of detailed clinical guidelines leaves clinicians’ questions on the practical management of patients receiving cladribine tablets for the treatment of relapsing multiple sclerosis (MS) unanswered.
Per Soelberg Sørensen, Diego Centonze, Gavin Giovannoni, Xavier Montalban, Daniel Selchen, Patrick Vermersch, Heinz Wiendl, Bassem Yamout, Hashem Salloukh, Peter Rieckmann   +9 more
doaj   +1 more source

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel, Sabrina Bänsch, Laura Adam, Nathan Fekade, Alessandra Rünger, Tim Zell, Daniel J. Smit, Julian Kött, Isabel Heidrich, Michael Weichenthal, Selma Ugurel, Ulrike Leiter, Peter Mohr, Alexandra Geusau, Stephan Grabbe, Markus V. Heppt, Ralf Gutzmer, Jochen Utikal, Jan‐Christoph Simon, Sebastian Haferkamp, Laura Susok, Bastian Schilling, Edgar Dippel, Imke von Wasielewski, Jessica C. Hassel, Carola Berking, Stefan W. Schneider, Christoffer Gebhardt   +27 more
wiley   +1 more source

Outcome of hairy cell leukemia patients treated with cladribine – a 10-year single-center experience in Pakistan

Hematology, Transfusion and Cell Therapy, 2019
Introduction and objective: Hairy cell leukemia is an uncommon, indolent B-cell lymphoproliferative disorder. Therapy with cladribine (2-chlorodeoxyadenosine) is able to induce complete remission (CR) in the majority of patients after a single course of ...
Mohammad Faizan Zahid, Mohammad Qasim Mehdi, Natasha Ali   +2 more
doaj   +1 more source

Health Literacy and Unmet Needs in Patients With Multiple Sclerosis: A Cross‐Sectional Study

Journal of Clinical Nursing, EarlyView.
ABSTRACT Aims To identify a correlation between unmet needs and HL levels in people with Multiple Sclerosis (pwMS) and to evaluate how sociodemographic characteristics influence HL levels and unmet needs. Design A cross‐sectional study. Methods The study was conducted using a questionnaire including the HLS19‐Q12 to assess HL and the Long‐term Unmet ...
Francesco Pastore, Barbara Forastefano, Valentina Simonetti, Tommaso Guerra, Giancarlo Cicolini, Pietro Iaffaldano, Dania Comparcini   +6 more
wiley   +1 more source

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis

Neuropsychiatric Disease and Treatment, 2010
Julie A Murphy, Jacklyn A Harris, Andrew J CrannageSt Louis College of Pharmacy, St Louis, MO, USAAbstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system.
Julie A Murphy, Jacklyn A Harris, Andrew J Crannage   +2 more
doaj  

Identifying Cladribine prescription pattern in MS: an Italian multicentre study

Therapeutic Advances in Neurological Disorders
Background: Characterizing Cladribine tablets prescription pattern in daily clinical practice is crucial for optimizing multiple sclerosis (MS) treatment.
Aurora Zanghì, Roberta Fantozzi, Matteo Foschi, Elisabetta Signoriello, Matilde Inglese, Giacomo Lus, Diego Centonze, Andrea Surcinelli, Tommaso Sirito, Simona Bonavita, Carlo Avolio, Emanuele D’Amico   +11 more
doaj   +1 more source

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management

American Journal of Hematology, Volume 101, Issue 9, Page 2393-2411, September 2026.
ABSTRACT Disease Overview The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
Guillermo Garcia‐Manero
wiley   +1 more source

Experience of cladribine tablets usage in the treatment of multiple sclerosis in the Multiple Sclerosis Centre of the Khanty-Mansi Autonomous Area — Yugra

Неврология, нейропсихиатрия, психосоматика
Cladribine is a tablet preparation for the treatment of relapsing-remitting multiple sclerosis (RRMS), which is used as an immune reconstitution therapy.
A. A. Sokolova, L. I. Anischenko, L. S. Zemlyanushin, E. A. Rubtsova   +3 more
doaj   +1 more source

Langerhans Cell Histiocytosis in Adults: A Canadian Multicenter Case Series

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Langerhans cell histiocytosis (LCH) is a rare clonal myeloid neoplasm. Canadian data on clinical characteristics, molecular profile, and treatment outcomes is limited. This study aims to report the initial experience of a Canadian rare diseases program, reflecting “real‐world” diagnostic pathways, referral patterns, and treatment heterogeneity
Stephanie Quon, Yaswanta Gummadi, Ibrahim Elsharawi, Jessica Dobson, Mariam Goubran, Ryan J. Stubbins, Eli L. Diamond, Luke Y. C. Chen   +7 more
wiley   +1 more source

Therapy with cladribine is efficient and safe in patients previously treated with natalizumab

Therapeutic Advances in Neurological Disorders, 2019
Background: The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML)
Nora Möhn, Thomas Skripuletz, Kurt-Wolfram Sühs, Sylvia Menck, Elke Voß, Martin Stangel   +5 more
doaj   +1 more source